Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans
Irving H. Fox(Takeda (United States)), John M. Maraganore(Biogen (United States)), Elizabeth Levin(University of Minnesota), Peter Loynds(Biogen (United States)), Tim Mant(Guy's Hospital), Jane Eisner(Biogen (United States)), Kathleen Findlen(Biogen (United States)), Don Hanson(Biogen (United States)), John G. Wagner(University of Michigan), Adrian Dawson(Biogen (United States))
Cited by 181
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694